IL161192A0 - Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents - Google Patents
Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agentsInfo
- Publication number
- IL161192A0 IL161192A0 IL16119202A IL16119202A IL161192A0 IL 161192 A0 IL161192 A0 IL 161192A0 IL 16119202 A IL16119202 A IL 16119202A IL 16119202 A IL16119202 A IL 16119202A IL 161192 A0 IL161192 A0 IL 161192A0
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- dipeptidyl peptidase
- diabetic agents
- novel dipeptidyl
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0125446.5A GB0125446D0 (en) | 2001-10-23 | 2001-10-23 | Novel anti-diabetic agents |
| PCT/GB2002/004787 WO2003035067A1 (en) | 2001-10-23 | 2002-10-23 | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161192A0 true IL161192A0 (en) | 2004-08-31 |
Family
ID=9924376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16119202A IL161192A0 (en) | 2001-10-23 | 2002-10-23 | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7144886B2 (ko) |
| EP (1) | EP1450794A1 (ko) |
| JP (1) | JP2005510499A (ko) |
| KR (1) | KR20040049321A (ko) |
| CN (1) | CN1329375C (ko) |
| AR (1) | AR037247A1 (ko) |
| CA (1) | CA2464256A1 (ko) |
| GB (1) | GB0125446D0 (ko) |
| HU (1) | HUP0402403A3 (ko) |
| IL (1) | IL161192A0 (ko) |
| MX (1) | MXPA04003828A (ko) |
| NO (1) | NO20042114L (ko) |
| NZ (1) | NZ532044A (ko) |
| PL (1) | PL370149A1 (ko) |
| RU (1) | RU2004110055A (ko) |
| UY (1) | UY27511A1 (ko) |
| WO (1) | WO2003035067A1 (ko) |
| ZA (1) | ZA200402500B (ko) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| ATE370943T1 (de) | 2001-06-27 | 2007-09-15 | Smithkline Beecham Corp | Fluoropyrrolidine als dipeptidyl-peptidase inhibitoren |
| DE60235212D1 (de) | 2001-06-27 | 2010-03-11 | Smithkline Beecham Corp | Fluoropyrrolidine als Dipeptidylpeptidasehemmer |
| ES2296962T3 (es) | 2001-06-27 | 2008-05-01 | Smithkline Beecham Corporation | Pirrolidinas como inhibidores de dipeptidil peptidasa. |
| ZA200508439B (en) | 2003-05-05 | 2007-03-28 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
| US20040229848A1 (en) * | 2003-05-05 | 2004-11-18 | Hans-Ulrich Demuth | Glutaminyl based DP IV-inhibitors |
| BRPI0415409A (pt) | 2003-10-15 | 2006-12-05 | Probiodrug Ag | uso de efetuadores de ciclases de glutaminila e glutamato |
| DE10348023A1 (de) * | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| DE10348044A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| CA2544573A1 (en) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| EP2839832A3 (en) | 2003-11-17 | 2015-06-24 | Novartis AG | Use of dipeptidyl peptidase IV inhibitors |
| BRPI0507007A (pt) | 2004-01-20 | 2007-06-05 | Novartis Ag | formulação e processo de compressão direta |
| AU2005210004B2 (en) | 2004-02-05 | 2010-10-28 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| MX2007011453A (es) | 2005-04-22 | 2008-02-12 | Alantos Pharmaceuticals Holding Inc | Inhibidores de la dipeptidil peptidasa-iv. |
| MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| KR20100114944A (ko) * | 2005-08-11 | 2010-10-26 | 에프. 호프만-라 로슈 아게 | Ｄｐｐ-ｉｖ 억제제를 포함하는 약학 조성물 |
| RS52110B2 (sr) | 2005-09-14 | 2018-05-31 | Takeda Pharmaceuticals Co | Inhibitori dipeptidil peptidaze za lečenje dijabetesa |
| CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP2410330A3 (en) | 2006-04-11 | 2012-06-13 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual |
| WO2007116092A1 (en) | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| SI2091948T1 (sl) | 2006-11-30 | 2012-07-31 | Probiodrug Ag | Novi inhibitorji glutaminil ciklaze |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| EP2146210A1 (en) * | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
| EP2542549B1 (en) | 2010-03-03 | 2016-05-11 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| EP2556056A1 (en) | 2010-04-06 | 2013-02-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| EA201390421A1 (ru) | 2010-09-22 | 2013-09-30 | Арена Фармасьютикалз, Инк. | Модуляторы рецептора gpr119 и лечение связанных с ним нарушений |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| US20140018371A1 (en) | 2011-04-01 | 2014-01-16 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
| JP2018507914A (ja) | 2015-03-09 | 2018-03-22 | インテクリン・セラピューティクス・インコーポレイテッド | 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 |
| WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
| JP2020515639A (ja) | 2017-04-03 | 2020-05-28 | コヒラス・バイオサイエンシズ・インコーポレイテッド | 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959248A (en) * | 1974-04-03 | 1976-05-25 | Merck & Co., Inc. | Analogs of thyrotropin-releasing hormone |
| IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
| GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
-
2001
- 2001-10-23 GB GBGB0125446.5A patent/GB0125446D0/en not_active Ceased
-
2002
- 2002-10-22 AR ARP020103995A patent/AR037247A1/es unknown
- 2002-10-22 UY UY27511A patent/UY27511A1/es not_active Application Discontinuation
- 2002-10-23 PL PL02370149A patent/PL370149A1/xx not_active Application Discontinuation
- 2002-10-23 HU HU0402403A patent/HUP0402403A3/hu unknown
- 2002-10-23 NZ NZ532044A patent/NZ532044A/en unknown
- 2002-10-23 CN CNB028208544A patent/CN1329375C/zh not_active Expired - Fee Related
- 2002-10-23 CA CA002464256A patent/CA2464256A1/en not_active Abandoned
- 2002-10-23 RU RU2004110055/04A patent/RU2004110055A/ru not_active Application Discontinuation
- 2002-10-23 IL IL16119202A patent/IL161192A0/xx unknown
- 2002-10-23 WO PCT/GB2002/004787 patent/WO2003035067A1/en not_active Application Discontinuation
- 2002-10-23 JP JP2003537634A patent/JP2005510499A/ja not_active Withdrawn
- 2002-10-23 KR KR10-2004-7005917A patent/KR20040049321A/ko not_active Application Discontinuation
- 2002-10-23 MX MXPA04003828A patent/MXPA04003828A/es active IP Right Grant
- 2002-10-23 EP EP02801961A patent/EP1450794A1/en not_active Withdrawn
- 2002-10-23 US US10/491,288 patent/US7144886B2/en not_active Expired - Fee Related
-
2004
- 2004-03-30 ZA ZA200402500A patent/ZA200402500B/xx unknown
- 2004-05-19 NO NO20042114A patent/NO20042114L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1329375C (zh) | 2007-08-01 |
| HUP0402403A2 (hu) | 2005-04-28 |
| GB0125446D0 (en) | 2001-12-12 |
| MXPA04003828A (es) | 2004-07-16 |
| KR20040049321A (ko) | 2004-06-11 |
| HUP0402403A3 (en) | 2009-05-28 |
| US7144886B2 (en) | 2006-12-05 |
| AR037247A1 (es) | 2004-11-03 |
| PL370149A1 (en) | 2005-05-16 |
| CN1575171A (zh) | 2005-02-02 |
| CA2464256A1 (en) | 2003-05-01 |
| NZ532044A (en) | 2005-03-24 |
| RU2004110055A (ru) | 2005-10-20 |
| UY27511A1 (es) | 2003-04-30 |
| WO2003035067A1 (en) | 2003-05-01 |
| US20050004205A1 (en) | 2005-01-06 |
| ZA200402500B (en) | 2005-01-24 |
| JP2005510499A (ja) | 2005-04-21 |
| EP1450794A1 (en) | 2004-09-01 |
| NO20042114L (no) | 2004-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161192A0 (en) | Novel dipeptidyl peptidase iv (dp-iv) inhibitors as anti-diabetic agents | |
| EP1465891A4 (en) | INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | |
| PL370220A1 (en) | Inhibitors of dipeptidyl peptidase iv | |
| PL370551A1 (en) | N-substituted pyrrolidin derivatives as dipeptidyl peptidase iv inhibitors | |
| IL151588A0 (en) | Inhibitors of dipeptidyl peptidase iv | |
| AU2003286776A1 (en) | Novel inhibitors of dipeptidyl peptidase iv | |
| AU2003207881A1 (en) | Dipeptidyl peptidase inhibitors | |
| HK1061030A1 (en) | Rho-kinase inhibitors | |
| HK1061029A1 (en) | Rho-kinase inhibitors | |
| IL174608A0 (en) | Pyridine compounds as inhibitors of dipeptidyl peptidase iv | |
| HK1049330A1 (en) | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv, processes for their preparation, and their use | |
| HUS1400007I1 (hu) | Dipeptidil-peptidáz inhibitorok | |
| SI2517706T1 (sl) | Postopki in sestavki za izdelavo dipeptidil peptidaznih IV inhibitorjev in njihovih intermediatov | |
| PL370909A1 (en) | Cis-imidazolines as mdm2 inhibitors | |
| EP1401453A4 (en) | PROTEASE INHIBITORS | |
| AU2002315472A1 (en) | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | |
| PL366704A1 (en) | Novel compounds for use as hiv protease inhibitors | |
| ZA200403090B (en) | N-substituted pyrrolidin derivatives as dipeptidyl peptidase IV inhibitors. | |
| AU2002216425A1 (en) | Dipeptidyl peptidase IV inhibitor | |
| AUPR975701A0 (en) | Dipeptidyl peptidase-iv inhibitor |